It is a 29-amino acid polypeptide representing the 129 fragment from endogenous human GHRH, thought to be the shortest fully functional fragment of GHRH
While these processes support their proposed healing advantages, they are also involved in tumour growth
Retrieved June 11, 2025, from Palmer, R
It stimulates lipolysis (breakdown of stored fats) and inhibits lipogenesis (formation of new fat), primarily via activation of -adrenergic and AMP-activated protein kinase (AMPK) pathways
However, the largest Phase IIb trial involving 536 subjects failed to demonstrate statistically significant weight loss compared to placebo at the primary 12-week endpoint, leading Metabolic Pharmaceuticals to terminate development in 2007
Harvard Medical School (2017)